Mabwell Shanghai Bioscience Co Ltd
SSE:688062
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.22
36.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Mabwell Shanghai Bioscience Co Ltd
Cash from Financing Activities
Mabwell Shanghai Bioscience Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mabwell Shanghai Bioscience Co Ltd
SSE:688062
|
Cash from Financing Activities
¥444.9m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash from Financing Activities
¥2.6B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cash from Financing Activities
¥960.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Financing Activities
-¥893.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash from Financing Activities
-¥1.2B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Financing Activities
-¥2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-39%
|
|
Mabwell Shanghai Bioscience Co Ltd
Glance View
Mabwell (Shanghai) Bioscience Co., Ltd. engages in the research and development, production and sales of therapeutic biological products. The company is headquartered in Shanghai, Shanghai and currently employs 1,052 full-time employees. The company went IPO on 2022-01-18. The firm's main businesses include the establishment of new varieties of drugs and the discovery of some early projects, the organization and development of preclinical research and pharmacological effects, and the development of drugs for preclinical research. The firm is also engaged in the organization, management and development of clinical trials of research species. The firm's research on drugs covers autoimmune, tumor, metabolism, ophthalmology, infection and other disease fields. The firm conducts business in domestic and foreign markets.
See Also
What is Mabwell Shanghai Bioscience Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
444.9m
CNY
Based on the financial report for Dec 31, 2023, Mabwell Shanghai Bioscience Co Ltd's Cash from Financing Activities amounts to 444.9m CNY.
What is Mabwell Shanghai Bioscience Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
1%
Over the last year, the Cash from Financing Activities growth was -88%. The average annual Cash from Financing Activities growth rates for Mabwell Shanghai Bioscience Co Ltd have been -27% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
